Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ASCO 2023 Highlights on the MIRASOL trial in PT-resistant adv. high-grade epithelial Ovarian Cancer

Reporting from ASCO 2023, Rowan Miller discusses practice changing results from the MIRASOL study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian cancer.

Abstract: LBA5507 - Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression, presented by Kathleen Moore.

The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/oncology-news/esmo-videos

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.